A Phase 3 interventional study of Ezetimibe/Rosuvastatin/Candesartan/Amlodipine and Candesartan/Amlodipine in Hypertension and Primary Hypercholesterolaemia, sponsored by Hyundai Pharm. Enrolling by invitation at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.
Sponsored by Hyundai Pharm · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ezetimibe in Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. Ezetimibe · Hypertension.
Among the 13 studies testing ezetimibe in Hypertension, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 3, and was the 12th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →1 of the 13 studies testing ezetimibe in Hypertension is open now, in 1 country.
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 65 across the 13 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 7 most frequent:
Hyundai Pharm is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Hyundai Pharm has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ezetimibe in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia
This trial is a phase 3 study to evaluate the efficacy and safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia.
This is multi-center, double-blind, Active-controlled, parallel-group, phase 3 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Oral tablet, QD
Drug: Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
Oral tablet, QD
Drug: Candesartan/Amlodipine
Oral tablet, QD
Drug: Candesartan/Rosuvastatin/Ezetimibe
Drug pages: Ezetimibe · Rosuvastatin · Candesartan · Amlodipine
PO, QD, 8 weeks
Drug pages: Candesartan · Amlodipine
PO, QD, 8 weeks
Drug pages: Candesartan · Rosuvastatin · Ezetimibe
PO, QD, 8 weeks
Low density lipoprotein cholesterol (LDL-C)
LDL-C change at Week 8 compared HODO-2224-1 + HODO-2224-4 + HODO-2224-5 with HODO-2224
Time frame: baseline and week 8
Mean sitting systolic blood pressure (MSSBP)
MSSBP change at week 8 compared HODO-2224-2 + HODO-2224-3 + HODO-2224-6 with HODO-2224
Time frame: baseline and week 8
change of other Lipid profile
change of other Lipid profile
Time frame: 0, 4, 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in May 2025, 0 months.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 0 months is below that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Rosuvastatin · Candesartan · Amlodipine
Hyundai Pharm